Denosumab biosimilar (Hualan Biological Engineering)

地舒单抗生物类似药（华兰基因工程）

Report date: 2026/04/03 20:03:44

Base Information

Drug NameDenosumab biosimilar (Hualan Biological Engineering)
Drug Alias NameDenosumab biosimilar (Hualan Biological Engineering)重组抗RANKL全人源单克隆抗体注射液（华兰基因工程）Denosumab生物类似药（华兰基因工程）Denosumab生物仿制药（华兰基因工程）
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanBiologics > Biosimilar
Mechanisms of ActionTumor necrosis factor ligand superfamily member 11 inhibitors
TargetsTumor necrosis factor ligand superfamily member 11
Therapy Area/IndicationsBone metastasesGlucocorticoid-induced osteoporosisSolid tumours +[8] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusNDA/BLA
Highest Status in ChinaNDA/BLA
Originator CompaniesHualan Ankang Biotechnology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesHualan Genetic Engineering (Henan) Co LtdHualan Ankang Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsBone metastasesGlucocorticoid-induced osteoporosisSolid tumours +[8] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A